AML Clinical Trials 2022

Browse 246 Aml Medical Studies Across 338 Cities
27 Phase 3 Trial · 2174 Aml Clinics

Display Results

All

Most EffectiveMost SafeSenior FriendlyPediatricNo Placebo

Clinical Trials AML Clinical Trials 2022

Reviewed by Michael Gill, B. Sc.

Image of Baptist Health South Florida/Miami Cancer Institute in Miami, United States.

Phase-Based Progress Estimates

Regimen A: TBI/Thiotepa/Cyclophosphamidefor Leukemia, Myeloid, Acute

Waitlist Available

This trial will see if an investigational device helps reduce complications for blood stem cell transplants.

Waitlist Available

Baptist Health South Florida/Miami Cancer InstituteGuenther Koehne, MD, PhD

Image of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, United States.

Phase-Based Progress Estimates

Flotetuzumabfor Leukemia, Myeloid, Acute

This trial is testing if a new drug is safe and effective for people with a certain type of leukemia.

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsJonathan Webster, MDMacroGenics

Image of The University of Alabama at Birmingham in Birmingham, United States.

Phase-Based Progress Estimates

JNJ-75276617for Leukemia, Myeloid, Acute

This trial is testing a new drug to see what dose is safe to use with other treatments for AML. They will also expand to study the safety and tolerability of the new drug at the recommended Phase 2 dose.

The University of Alabama at Birmingham (+6 Sites)Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC

Image of Local Institution in Marina Del Rey, United States.

Phase-Based Progress Estimates

CC-95251for Myelodysplastic Syndromes

FDA Approved Drug

This trial is testing a new drug, CC-95251, to see if it is safe and works well against leukemia and certain types of cancer.

FDA Approved Drug

Local Institution (+14 Sites)Bristol-Myers SquibbBristol-Myers Squibb

Image of MDACC in Houston, United States.

Phase-Based Progress Estimates

DSP-5336for Leukemia, Myeloid, Acute

This trial is testing a new drug for people with a certain type of blood cancer who have not responded to other treatments.

MDACC (+5 Sites)Sumitomo Dainippon Pharma Oncology, Inc

Image of University of California San Diego Moores Cancer Center in La Jolla, United States.

Phase-Based Progress Estimates

CC-91633for Myelodysplastic Syndromes

This trial is testing a new drug, CC-91633, for people with relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes. The first part of the trial will test different doses of the drug to find a safe and tolerable dose. The second part of the trial will test the efficacy of the selected dose.

University of California San Diego Moores Cancer Center (+5 Sites)Tim Campbell, MD, PhDCelgene

Image of Childrens Hospital Colorado in Aurora, United States.

Phase-Based Progress Estimates

Arm 1: Diet Interventionfor Leukemia, Myeloid, Acute

This trial will test whether eating more fiber and less fat can help prevent recurring C. diff infections in cancer patients.

Childrens Hospital Colorado (+1 Sites)Catherine Lozupone

Image of Stanford University in Stanford, United States.

Phase-Based Progress Estimates

CC-486for Leukemia, Myeloid, Acute

FDA Approved Drug

This trial is testing a new drug combination to see if it is safe and effective for people with AML who have relapsed or who are refractory to other treatments.

FDA Approved Drug

Stanford University (+8 Sites)Kimberley Dilley, MD/MPHCelgene

Image of University of California San Diego Moores Cancer Center in La Jolla, United States.

Phase-Based Progress Estimates

VOR33for Leukemia, Myeloid, Acute

FDA Approved Drug

This trial is testing a new drug, VOR33, on people with AML who are having a HCT.

FDA Approved Drug

University of California San Diego Moores Cancer Center (+8 Sites)Vor Biopharma

Image of University of California, San Francisco in San Francisco, United States.

Phase-Based Progress Estimates

CC-90009for Leukemia, Myeloid, Acute

FDA Approved Drug

This trial is testing a new drug, CC-90009, to see if it is safe and effective when used with other drugs to treat acute myeloid leukemia.

FDA Approved Drug

University of California, San Francisco (+12 Sites)Michael Pourdehnad, M.D.AbbVie

Image of Colorado Blood Cancer Institute in Denver, United States.

Phase-Based Progress Estimates

CYNK-001for Hematologic Diseases

This trial will study the safety and effectiveness of a new leukemia treatment that usesNK cells.

Colorado Blood Cancer Institute (+8 Sites)Solveig Ericson, MD, PhDCelularity Incorporated

Image of City of Hope in Duarte, United States.

Phase-Based Progress Estimates

Cusatuzumabfor Leukemia, Myeloid, Acute

Waitlist Available

FDA Approved Drug

This trial will help researchers learn more about how safe and tolerable cusatuzumab is when used with different AML treatments.

Waitlist Available

FDA Approved Drug

City of Hope (+14 Sites)Janssen Research & Development, LLC Clinical TrialJanssen Research & Development, LLC

Image of O'Neal Comprehensive Cancer Center in Birmingham, United States.

Phase-Based Progress Estimates

DFP-10917for Leukemia, Myeloid, Acute

FDA Approved Drug

This trial is testing an experimental treatment called DFP-10917 against standard treatments for relapsed or refractory acute myeloid leukemia (AML). Patients in the experimental arm will receive DFP-10917 by continuous intravenous infusion for 14 days, followed by a 14-day resting period, for up to 6 cycles. Patients in the control arm will receive standard treatments, which may include non-intensive reinduction or intensive reinduction, depending on the patient's prior induction treatment.

FDA Approved Drug

O'Neal Comprehensive Cancer Center (+36 Sites)Tapan Kadia, MDDelta-Fly Pharma, Inc.

Image of Weill Cornell Medical College in New York, United States.

Phase-Based Progress Estimates

CPX-351for Leukemia, Myeloid, Acute

Waitlist Available

FDA Approved Drug

This trial is testing a combination of two treatments, CPX-351 and haplo-cord graft stem cell transplantation, to see if they are effective in treating subjects with relapsed or refractory AML or myelodysplastic syndrome.

Waitlist Available

FDA Approved Drug

Weill Cornell Medical CollegeKoen van Besien, MD, PhDJazz Pharmaceuticals

Image of Weill Cornell Medical College in New York, United States.

Phase-Based Progress Estimates

CPX-351for Leukemia, Myeloid, Acute

Waitlist Available

FDA Approved Drug

This trial is testing a new cancer treatment in elderly patients with AML who have not responded to other treatments. The treatment will be given intensively, and the outcomes will be measured by how well the patients respond and how safe the treatment is.

Waitlist Available

FDA Approved Drug

Weill Cornell Medical CollegeEllen K Ritchie, MDJazz Pharmaceuticals

Image of Southern Cancer Center - USOR in Daphne, United States.

Phase-Based Progress Estimates

Pevonedistatfor Leukemia, Myelomonocytic, Chronic

Waitlist Available

FDA Approved Drug

This trial is testing whether adding pevonedistat to azacitidine helps people with MDS, CMML, or low-blast AML live longer without disease progression or death.

Waitlist Available

FDA Approved Drug

Southern Cancer Center - USOR (+2 Sites)Medical Director Clinical ScienceMillennium Pharmaceuticals, Inc.

Image of Cancer Care Manitoba in Winnipeg, Canada.

Phase-Based Progress Estimates

AG-120 (ivosidenib) With Azacitidinefor Leukemia

Waitlist Available

FDA Approved Drug

This trial is testing a new drug, AG-120, to see if it can help people with a certain type of leukemia who have not been treated before. The trial will compare AG-120 to a placebo, given with a standard treatment, azacitidine. The study will measure how well the participants do in terms of survival and response to treatment.

Waitlist Available

FDA Approved Drug

Cancer Care Manitoba (+1 Sites)

Image of Massachusetts General Hospital in Boston, United States.

Phase-Based Progress Estimates

MBG453for Hematologic Diseases

Waitlist Available

FDA Approved Drug

This trial is testing the safety and tolerability of two drugs, MBG453 and PDR001, either alone or in combination with each other or with other drugs. The goal is to find recommended doses for future studies.

Waitlist Available

FDA Approved Drug

Massachusetts General Hospital (+2 Sites)Novartis PharmaceuticalsNovartis Pharmaceuticals

Image of Yale Cancer Center in New Haven, United States.

Phase-Based Progress Estimates

CC-90009for Myelodysplastic Syndromes

This trial is testing a new drug for people with leukemia or myelodysplastic syndrome who have not responded to other treatments.

Yale Cancer Center (+5 Sites)August Dietrich, MDCelgene

Image of Mayo Clinic Jacksonville in Jacksonville, United States.

Phase-Based Progress Estimates

H3B-8800for Myelodysplastic Syndromes

This trial is testing a new drug, H3B-8800, for people with myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. The goal is to see if it is safe and to learn how it works in the body.

Mayo Clinic Jacksonville (+6 Sites)Keisuke Kuida, MD, PhDHemavant Sciences GmbH

Image of City of Hope in Duarte, United States.

Phase-Based Progress Estimates

AG-120for Leukemia, Myeloid, Acute

Waitlist Available

FDA Approved Drug

This trial will study two drugs, AG-120 and AG-221, in combination with azacitidine, to see if they are safe and effective in treating AML with IDH1 or IDH2 mutations.

Waitlist Available

FDA Approved Drug

City of Hope (+12 Sites)Ira Gupta, MDCelgene

Image of Banner MD Anderson Cancer Center in Gilbert, United States.

Phase-Based Progress Estimates

Iomab-Bfor Leukemia, Myeloid, Acute

Waitlist Available

This trial is testing a new treatment for AML patients who have relapsed or are unresponsive to other treatments. The new treatment consists of a reduced intensity conditioning regimen in conjunction with Iomab-B and allogeneic hematopoietic stem cell transplant.

Waitlist Available

Banner MD Anderson Cancer Center (+23 Sites)Mark Berger, MDActinium Pharmaceuticals

Image of Mayo Clinic Cancer Center in Jacksonville, United States.

Phase-Based Progress Estimates

BI 836858for Leukemia, Myeloid, Acute

Waitlist Available

FDA Approved Drug

This trial is testing a new drug, BI 836858, to see if it is safe and effective when used with the drug decitabine to treat acute myeloid leukemia. The trial has three phases. In the first phase, different doses of BI 836858 are tested to see what the maximum tolerated dose is. In the second phase, the safety and efficacy of BI 836858 in combination with decitabine is compared to decitabine alone. The third phase is designed to see if BI 836858 is effective in treating people with acute myeloid leukemia.

Waitlist Available

FDA Approved Drug

Mayo Clinic Cancer Center (+3 Sites)Boehringer IngelheimBoehringer Ingelheim

Image of Washington University School of Medicine in Saint Louis, United States.

Phase-Based Progress Estimates

Leukapheresisfor Leukemia, Myeloid, Acute

Waitlist Available

FDA Approved Drug

This trial is for patients with relapsed or refractory acute myeloid leukemia and myeloid dysplastic syndromes. Doctors will give chemotherapy to patients before giving them an infusion of donor natural killer cells. This is to help stop the growth of cancer cells and keep the patient's immune system from rejecting the donor cells.

Waitlist Available

FDA Approved Drug

Washington University School of MedicineAmanda Cashen, M.D.ImmunityBio, Inc.

Image of Arizona Oncology Associates, P.C. in Phoenix, United States.

Phase-Based Progress Estimates

Oral Azacitidinefor Leukemia, Myeloid, Acute

Waitlist Available

FDA Approved Drug

This trial is studying oral azacitidine to see how well it works in treating patients with acute myeloid leukemia or myelodysplastic syndromes.

Waitlist Available

FDA Approved Drug

Arizona Oncology Associates, P.C. (+66 Sites)Barry Skikne, MDCelgene

25 Aml Clinical Trials Near Me

Top Hospitals for Aml Clinical Trials

Image of M D Anderson Cancer Center in Texas.

M D Anderson Cancer Center

Houston

39Active Trials

93All Time Trials for Aml

1999First Aml Trial

Image of MD Anderson Cancer Center in Texas.

MD Anderson Cancer Center

Houston

26Active Trials

94All Time Trials for Aml

2001First Aml Trial

Top Cities for Aml Clinical Trials

Image of Houston in Texas.

Houston

112Active Trials

M D Anderson Cancer CenterTop Active Site

Image of New York in New York.

New York

82Active Trials

Memorial Sloan Kettering Cancer CenterTop Active Site